# Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty

> **NCT06398275** · PHASE2 · UNKNOWN · sponsor: **University Hospital of Split** · enrollment: 80 (estimated)

## Conditions studied

- Remimazolam
- Emergence Delirium
- Rhinoplasty

## Interventions

- **DRUG:** Remimazolam 20 MG Injection [Byfavo]
- **DRUG:** NaCl 0.9%

## Key facts

- **NCT ID:** NCT06398275
- **Lead sponsor:** University Hospital of Split
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-06
- **Primary completion:** 2024-09
- **Final completion:** 2024-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398275, "Remimazolam for Emergence Delirium Prevention in Patients Undergoing Rhinoseptoplasty, FESS or Septoplasty". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06398275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*